Legend Biotech (NASDAQ: DADA) is one of 64 publicly-traded companies in the “Computer programming, data processing, & other computer related” industry, but how does it contrast to its rivals? We will compare Legend Biotech to similar businesses based on the strength of its dividends, analyst recommendations, valuation, profitability, risk, earnings and institutional ownership.
Institutional and Insider Ownership
14.5% of Legend Biotech shares are held by institutional investors. Comparatively, 52.3% of shares of all “Computer programming, data processing, & other computer related” companies are held by institutional investors. 14.3% of shares of all “Computer programming, data processing, & other computer related” companies are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Earnings & Valuation
This table compares Legend Biotech and its rivals revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Legend Biotech||$437.76 million||-$235.82 million||-7.16|
|Legend Biotech Competitors||$7.75 billion||$1.49 billion||106.77|
Legend Biotech’s rivals have higher revenue and earnings than Legend Biotech. Legend Biotech is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
This is a summary of current recommendations and price targets for Legend Biotech and its rivals, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Legend Biotech Competitors||1019||3487||6900||324||2.56|
Legend Biotech currently has a consensus price target of $22.00, indicating a potential downside of 20.00%. As a group, “Computer programming, data processing, & other computer related” companies have a potential upside of 4.25%. Given Legend Biotech’s rivals stronger consensus rating and higher probable upside, analysts plainly believe Legend Biotech has less favorable growth aspects than its rivals.
This table compares Legend Biotech and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Legend Biotech Competitors||-11.49%||-59.90%||-5.93%|
Legend Biotech rivals beat Legend Biotech on 9 of the 12 factors compared.
About Legend Biotech
New Dada owns and operates an online crowdsourcing logistics portal and provides local instant delivery service. The company was formerly known as Dada Nexus Limited and changed its name to New Dada in April 2016. New Dada was founded in 2014 and is based in Shanghai, China.
Receive News & Ratings for Legend Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Legend Biotech and related companies with MarketBeat.com's FREE daily email newsletter.